Ieq Capital LLC Purchases 21,706 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Ieq Capital LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 109.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 41,521 shares of the medical research company’s stock after acquiring an additional 21,706 shares during the period. Ieq Capital LLC’s holdings in IQVIA were worth $8,159,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the third quarter valued at approximately $27,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares in the last quarter. Synergy Asset Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at approximately $33,000. Assetmark Inc. lifted its holdings in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares in the last quarter. Finally, Concord Wealth Partners purchased a new stake in shares of IQVIA during the third quarter valued at approximately $57,000. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research analyst reports. Barclays decreased their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Truist Financial reaffirmed a “buy” rating and set a $263.00 price target (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.22.

Insider Activity at IQVIA

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is owned by corporate insiders.

IQVIA Price Performance

Shares of NYSE IQV opened at $194.01 on Friday. The stock has a market cap of $34.16 billion, a PE ratio of 25.87, a price-to-earnings-growth ratio of 1.98 and a beta of 1.48. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a fifty day moving average of $199.86 and a 200-day moving average of $216.95.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.86 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.